Iclusig (ponatinib) / Takeda, Otsuka, Incyte, Endo, Specialised Therap, Pint Pharma, Biologix Pharma - LARVOL DELTA

Zongertinib-tolerant cells enhanced sensitivity to Topo1 inhibition in Her2-positive NCSLC (AACR 2026) - "For the treatment of Her2 mutated/amplified NSCLC, the antibody-drug conjugate Trastuzumab deruxtecan, several Her2-selective inhibitors, such as zongertinib and sevabertinib, have shown beneficial efficacy in clinical settings...Drug screening revealed that zongerR cells exhibited sensitivity to the multi-tyrosine kinase inhibitor ponatinib and foretinib. Additionally, PI3K/AKT pathway inhibitors (PI3Ki) such as GDC0941 and mTOR inhibitor PP242 also markedly suppressed the survival of zongerR cells in combination with zongertinib...Currently, zongertinib and T-Dxd have been approved for Her2-positive NSCLC, whereas treatment strategies to prolong the durable response have not been well-established. Further investigations were needed, but our findings suggested that T-DXd treatment after zongertinib may be a potential therapeutic strategy in a subset of Her2-positive NSCLC."

Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

Tyrosine kinase inhibitors, chronic myeloid leukemia, and pregnancy: pharmacotherapeutic challenges and recommendations. (PubMed, Expert Opin Pharmacother) - "All TKIs are not recommended during the first trimester due to their risk of teratogenesis, but imatinib and nilotinib may be cautiously used from Weeks 16-18 onward. Non-TKI therapies, such as hydroxyurea and interferon-α, are considered safe throughout pregnancy. Data on ponatinib and asciminib remain insufficient to allow the safe use of these agents during pregnancy. Future research should aim to improve treatment-free remission rates through novel agents and combination strategies to allow a higher proportion of younger patients to discontinue therapy. Clinicians should always counsel women on pregnancy risks during therapy while reassuring male patients of TKI safety when fathering children."

Journal • Review • Chronic Myeloid Leukemia • Hematological Malignancies • Leukemia • Oncology • ABL1

Venetoclax plus inotuzumab ozogamicin for relapsed and refractory ALL: Results of a phase I trial (ASH 2025) - P1 | "Due to distinct mechanisms of action and non-overlapping toxicities, we hypothesized that adding VEN to INO would be safe and effective. This investigator-sponsored phase I study (NCT05016947) enrolled pts ≥18 years with CD22+ (≥20% ofblasts) R/R ALL (≥5% bone marrow [BM] blasts) or lymphoblastic lymphoma (LBL, BM <5% blasts).Philadelphia chromosome-negative (Ph-) pts had received ≥1 line of therapy; Ph+ pts were ponatinib(PON)-refractory or ineligible...Dexamethasone (10 mg/m2) was given during Lead-In and D1-4 of C1 Induction...BH3 profiling showed that ptsMRD- by C2 had lower pre-treatment mitochondrial apoptotic priming.Of the 21 CR patients, 1 pt (KMT2Ar) progressed during C2, and the remaining 20 pts (95.2%) wereconsolidated with blinatumomab (n=9, 42.9%), SCT (n=14, 66.7%, 6 after blinatumomab), DLI (n=1), XRT(n=1), or POMP (n=1)... VEN can be safely added to INO in pts with R/R CD22+ ALL/LBL including Ph+ ALL, with a very high anddurable rate of MRD- CR...."

P1 data • CNS Disorders • Febrile Neutropenia • Gastrointestinal Disorder • Hepatology • Lymphoblastic Lymphoma • Lymphoma • Neutropenia • Thrombocytopenia • KMT2A

Dual-specificity phosphatase 21 enhances the sensitivity of imatinib-resistant chronic myeloid leukemia cells to ponatinib through GATA-1-mediated erythroid differentiation. (PubMed, Biochem Biophys Res Commun) - "GATA-1 knockdown eliminated DUSP21's effects on erythroid differentiation and ponatinib sensitivity in K562 and K562R cells. Collectively, these findings suggest that DUSP21 acts as a positive regulator of erythroid differentiation in CML cells, and its overexpression sensitizes imatinib-resistant CML cells to ponatinib via GATA-1-mediated erythroid differentiation."

Journal • Chronic Myeloid Leukemia • Hematological Malignancies • Leukemia • Oncology • ABL1 • BCR • GATA1

Molecular characterization and predictors of relapse in patients with Ph + ALL after frontline ponatinib and blinatumomab. (PubMed, J Hematol Oncol) - P2 | "WBC ≥ 70 × 109/L is a high-risk feature in patients with Ph + ALL receiving frontline blinatumomab and ponatinib and may supersede the prognostic importance of baseline molecular features. Alternative frontline treatment strategies may be needed for these patients to reduce the risk of relapse and improve long-term outcomes."

Journal • Acute Lymphocytic Leukemia • Hematological Malignancies • Leukemia • Oncology • ABL1 • CD19 • IKZF1 • VPREB1

Ponatinib as a consolidation strategy for a second attempt at TKI discontinuation in chronic myeloid leukemia: Interim results from the restop Trial (ASH 2025) - P2 | "The potencyof the third-generation TKI ponatinib makes it a promising candidate to deepen molecular response priorto a second discontinuation attempt.METHODSResToP is a phase II, multicenter, open-label, non-comparative clinical trial that enrolled adult patientswith chronic-phase CML who had previously failed a first TKI discontinuation attempt and hadsubsequently regained a sustained deep molecular response (MR4) for ≥1 year after restarting therapy.Patients received consolidation therapy with ponatinib 15 mg/day and acetylsalicylic acid 100 mg/day for2 years, followed by complete treatment withdrawal. The most frequent grade 1–2 toxicities werehypertension (14.7%), hepatotoxicity, arthralgia, and myalgia (each at 11.8%). One death unrelated totherapy was recorded.CONCLUSIONConsolidation therapy with ponatinib represents an effective and safe strategy for a second TKIdiscontinuation in CML patients after a prior failed withdrawal attempt."

Chronic Myeloid Leukemia • Hematological Malignancies • Hypertension • Leukemia • Musculoskeletal Pain • Myocardial Infarction • ABL1

HELICOBACTER PYLORI INFECTION IMPLICATES C-ABL KINASE IN Α-SYNUCLEIN SER129 PHOSPHORYLATION (ADPD 2026) - "Treatment with the c-Abl inhibitors, Ponatinib and Asciminib, effectively prevented the accumulation of pSer129 α-synuclein and reversed the associated gene expression changes induced by H. pylori or rotenone. These findings highlight the pivotal role of c-Abl in α-Synucleinopathies and provide insights into shared mechanisms between infection and pesticide exposure, offering potential therapeutic targets for Parkinson's disease and related pathologies involving α-Synuclein modification."

CNS Disorders • Infectious Disease • Movement Disorders • Parkinson's Disease • ABL1

Integrative computational pipeline for the in silico prioritization of potential KIF11-targeting drug candidates in glioblastoma. (PubMed, J Mol Graph Model) - "Among four prioritized compounds, Ponatinib demonstrated the most favorable binding free energy, while Pimavanserin exhibited stable conformational behavior during simulation. These findings provide an in-silico prioritization framework for potential KIF11-targeting compounds in GBM. Experimental validation in relevant cellular and in vivo models will be required to determine biological and therapeutic relevance."

Journal • Brain Cancer • CNS Tumor • Glioblastoma • Oncology • Solid Tumor • KIF11 • KIF20A • TOP2A

Novel Treatment Combinations for B-ALL May Help Patients Safely Achieve Remission: With Colin Vale, MD (Apple Podcasts) - "In our exclusive interview, Dr Vale discussed data from a phase 2 trial (NCT03263572) evaluating blinatumomab (Blincyto) plus ponatinib (Iclusig) in patients with Philadelphia chromosome–positive B-cell acute lymphoblastic leukemia. In addition to underscoring the findings and their clinical significance, Vale expanded on how the combination can improve patient quality of life by helping patients avoid procedures like allogeneic stem cell transplant."

Audio

Decitabine, venetoclax, and ponatinib for advanced phase chronic myeloid leukaemia and Philadelphia chromosome-positive acute myeloid leukaemia: a single-arm, single-centre phase 2 trial. (PubMed, Lancet Haematol) - P2 | "The combination of decitabine, venetoclax, and ponatinib is safe and shows promising activity in patients with advanced phase chronic myeloid leukaemia, including those with multiple previous therapies or high-risk disease features. Further studies evaluating chemotherapy and venetoclax-based combination strategies using newer-generation BCR::ABL1 tyrosine kinase inhibitors are warranted."

Journal • Metastases • P2 data • Acute Myelogenous Leukemia • Cardiovascular • Chronic Myeloid Leukemia • Febrile Neutropenia • Hematological Malignancies • Infectious Disease • Neutropenia • Oncology • ABL1

First results of the Phase III GIMEMA ALL2820 trial comparing ponatinib plus blinatumomab to imatinib and chemotherapy for newly diagnosed adult ph+ acute lymphoblastic leukemia patients (ASH 2025) - "Compared to the GIMEMA LAL2116 trial, anincrease in MRD negativity and less relapses were observed. A chemo-free approach should be the newstandard for adult Ph+ ALL."

Clinical • IO biomarker • P3 data • Acute Lymphocytic Leukemia • Cardiovascular • Hematological Disorders • Hematological Malignancies • Infectious Disease • Leukemia • Myocardial Infarction • Pneumonia • Renal Disease • Respiratory Diseases • Septic Shock • ABL1 • IKZF1

Primary efficacy analysis of phase II study investigating tyrosine kinase inhibitor (TKI) and inotuzumab ozogamicin-based therapy for newly diagnosed Philadelphia-chromosome positive acute lymphoblastic leukemia (Ph+ ALL) (ASH 2025) - "Tyrosine kinase inhibitor (TKI) + blinatumomab regimenshave demonstrated high MR4 rates and favorable overall survival (OS); however, these regimens includeup to 5 courses of blinatumomab which is a continuous 28-day infusion (Kantarjian et al, JCO 2024; Foa etal, JCO 2024)...Eligibilitycriteria includes newly diagnosed Ph+ ALL, age ≥ 18, ECOG ≤2, CD22+ on ≥20% blasts, and no centralnervous system (CNS) disease.Schema 1 was as follows; Course (C) 1 was (28 days) dasatinib (DAS) 140mg daily, dexamethasone (dex)10mg/m2 D1-7 & D15-21, and InO 0.8mg/m2 D8, 0.5mg/m2 D15 and D22...If MR4 was not achieved by end of C2 (EOC2), DAS was switched to ponatinib(PON)...TKI + InO-based therapy for newly diagnosed pts with Ph+ ALL has an MR3+ rate of 81% within 2 coursesand 100% of pts achieved MR4 and/or NGS MRD- disease by EOC3. No cases of VOD were seen withSchema 2. Given the excellent rates of MR3+ with limited cycles of InO, further development of thisinduction approach is..."

Clinical • P2 data • Acute Lymphocytic Leukemia • CNS Disorders • Hematological Malignancies • Hepatology • Infectious Disease • Leukemia • Pulmonary Disease • Respiratory Diseases • Septic Shock • IKZF1

Vodobatinib for patients with Philadelphia chromosome-positive chronic myeloid leukaemia resistant or intolerant to multiple lines of previous therapy: an open-label, multicentre, phase 1/2 trial. (PubMed, Lancet Haematol) - P1/2 | "Pooled analysis of the phase 1 and 2 studies showed clinically meaningful antileukaemic activity of vodobatinib and a tolerable safety profile in patients with advanced chronic myeloid leukaemia who previously received multiple TKIs, including ponatinib and asciminib, addressing an otherwise unmet clinical need. The phase 2 study was statistically underpowered and warrants further investigation in a phase 3, randomised controlled trial and in an earlier treatment setting of the disease."

Journal • P1/2 data • Acute Lymphocytic Leukemia • Chronic Myeloid Leukemia • Gastrointestinal Disorder • Hematological Disorders • Hematological Malignancies • Leukemia • Neutropenia • Oncology • Pulmonary Disease • Thrombocytopenia • ABL1

Characterization of adverse cutaneous effects in the setting of ponatinib, bosutinib, andasciminib for chronic myeloid leukemia patients (AACR 2026) - "BCR-ABL tyrosine kinase inhibitors (TKIs) are used in the treatment of chronic myeloid leukemia (CML) and include second- and third-generation agents: ponatinib, bosutinib, and asciminib. While cutaneous adverse events (cAEs) of first-generation TKIs such as imatinib are well-documented, real-world reports involving newer agents remain limited and poorly described...The significantly increased risk in females aligns with prior literature, possibly due to differences in body type, medication adherence, or reporting. Our limitations include retrospective design and single institution use."

Clinical • Chronic Myeloid Leukemia • Hematological Malignancies • Leukemia • Oncology • Squamous Cell Carcinoma • ABL1 • BCR

LEDGF/p75 drives chemoresistance in CML via JAK/STAT pathway modulation (AACR 2026) - "In KMT2A-wild-type (WT) AML cell lines U-937 and Kasumi-1, LEDGF/p75 depletion did not alter cytarabine sensitivity and the same trend was observed in WT T-ALL cell lines Jurkat and SupT-1...Interestingly, LEDGF/p75 KD in two WT KMT2A CML cell lines, K-562 and JUR-MK1, led to a significant reduction in proliferation upon vincristine treatment (IC50 K-562 Mock/KD: 2.61 ± 0.10 nM / 0.81 ± 0.09 nM and IC50 JUR-MK1 Mock/KD: 3.93 ± 0.35 nM / 2.37 ± 0.30 nM) and increased apoptosis with elevated caspase3. Treatment of K-562 cells with BCR-ABL inhibitors Imatinib and Ponatinib also showed decreased proliferation upon LEDGF/p75 depletion...Taken together, our result indicates that the role of LEDGF/p75 in therapy resistance is context dependent and varies across leukemic subtypes. We identify a previously unknown function of LEDGF/p75 in mediating drug resistance in CML cells acting through the JAK/STAT Pathway."

Breast Cancer • Chronic Myeloid Leukemia • Hematological Malignancies • Leukemia • Oncology • Prostate Cancer • Solid Tumor • T Acute Lymphoblastic Leukemia • ABL1 • BCL2A1 • BCL2L1 • BCR • CASP3 • KMT2A • STAT2 • STAT5

Randomized comparison of ponatinib versus imatinib in combination with chemotherapy in patients 55 years of age and older with newly diagnosed ph+ ALL: Molecular response and initial outcome analysis of the EWALL PH03 Study (ASH 2025) - P2 | "Moreover, the bispecific T-cell engager blinatumomab (BLIN) hasemerged as a potent front-line modality in Ph+ALL. In older pts with Ph+ALL receiving upfront reduced-intensity chemotherapy (EWALL), PONinduces a higher, albeit not significant, deep molecular response rate compared to IM, The safety profileof PON was consistent with known AEs and did not lead to a higher rate of withdrawals from studytreatment than IM. The impact on survival will require longer follow-up."

Clinical • Combination therapy • Acute Lymphocytic Leukemia • Hypertension • Pancreatitis • Thrombosis • ABL1 • BCR

HEARTBREAKING THERAPY: PONATINIB-ASSOCIATED NONISCHEMIC CARDIOMYOPATHY (ACC 2026) - "Case: A 75-year-old female with chronic-phase chronic myeloid leukemia (CML), previously treated with dasatinib, imatinib, and nilotinib, was started on ponatinib in June 2024. This case demonstrates the risk of anchoring on common causes of heart failure, emphasizing the need to consider drug-induced cardiomyopathy for timely diagnosis and management. Multiple studies (including PACE, OPTIC, PhALLCON) have reported heart failure with ponatinib, but the overall incidence remains low. This case additionally underscores the importance of cardiac surveillance in patients on TKIs, especially in those with prior exposure."

Cardiomyopathy • Cardiovascular • Chronic Kidney Disease • Chronic Myeloid Leukemia • Cognitive Disorders • Congestive Heart Failure • Heart Failure • Hematological Malignancies • Leukemia • Nephrology • Pulmonary Disease • Renal Disease

FROM B-CELL LEUKEMIA TREATMENT TO BREATHLESS: A CASE OF PONATINIB-INDUCED PULMONARY ARTERIAL HYPERTENSION (ACC 2026) - "Case: A 60-year-old female who received dasatinib and ponatinib before allogeneic stem cell transplant (SCT) for Ph-positive B-cell ALL presented with dyspnea one week after re-initiation of ponatinib...She was started on sildenafil and furosemide with mild clinical improvement and discharged with close follow up... PAH should be considered in the differential in patients on ponatinib therapy with new onset dyspnea."

Clinical • Hematological Malignancies • Leukemia • Pulmonary Arterial Hypertension • Pulmonary Embolism • Respiratory Diseases

LONG-TERM OUTCOMES OF ADULT PH+ ALL TREATED WITH DASATINIB OR IMATINIB BEFORE THE BLINATUMOMAB ERA: A RETROSPECTIVE ANALYSIS OF 250 PATIENTS FROM THE PALG REGISTRY (EBMT 2026) - "Background: The prognosis of Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph+ ALL) has improved substantially with the introduction of tyrosine kinase inhibitors (TKIs). In this pre-blinatumomab era subgroup analysis, adults with Ph+ ALL undergoing allo-HSCT achieved favorable long-term outcomes. Despite being part of a clinically high-risk subgroup (imatinib resistance or central nervous system involvement), patients receiving dasatinib demonstrated promising 10-year OS probability, exceeding that of imatinib and yielding statistical significance compared to that the Ph-negative ALL group. Rates, grades and involved sites of aGvHD, cGvHD, and causes of death did not differ significantly between groups, suggesting that survival differences may be driven mainly by disease control rather than transplant-related toxicity."

Retrospective data • Acute Graft versus Host Disease • Acute Lymphocytic Leukemia • Bone Marrow Transplantation • Chronic Graft versus Host Disease • Graft versus Host Disease • Hematological Malignancies • Immunology • Leukemia

OPTIMIZING TRANSPLANT OUTCOMES IN PHILADELPHIA CHROMOSOME–POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA WITH PRE-TRANSPLANT SECOND- AND THIRD-GENERATION TKIS AND POST-TRANSPLANT PROPHYLACTIC MAINTENANCE: A STUDY FROM THE EBMT ALWP (EBMT 2026) - "Peripheral blood stem cells were used in 84% of cases, with 79% receiving myeloablative conditioning, and 51% receiving total body irradiation.TKI use prior to transplant included imatinib (N=612, 64%), dasatinib (N=210, 22%), nilotinib (N= 96, 10%), and ponatinib (N=40, 4%). In this large, multicenter cohort of patients with Ph+ ALL undergoing allo-HCT in CR1, the use of second- and third-generation TKIs during induction was associated with superior survival outcomes compared to imatinib. Post-transplant TKI prophylaxis significantly improved survival regardless of pre-transplant MRD status. These findings support the incorporation of newer TKIs and prophylactic strategies in the transplant setting to optimize long-term outcomes in Ph+ ALL."

Clinical • Post-transplantation • Pre-transplantation • Acute Lymphocytic Leukemia • Graft versus Host Disease • Hematological Malignancies • Immunology • Leukemia • Transplantation

RESOURCE-ADAPTED IMMUNOTHERAPY BRIDGING TO ACHIEVE MRD-NEGATIVITY PRIOR TO ALLOGENEIC HSCT IN HIGH-RISK ALL: A SINGLE-CENTRE REAL-WORLD EXPERIENCE (EBMT 2026) - "We implemented a structured resource-adapted bridging program using blinatumomab and/or inotuzumab ozogamicin (InO) with feasibility-focused operational modifications...Bridging included blinatumomab in 6/9 (1 cycle in 5; 2 cycles in 1) and InO in 4/9 (3 doses each; dose-capped); one Ph+ multiply-relapsed post–CAR-T patient received ponatinib + asciminib + InO before transplant... A structured, feasibility-focused bridging program—combining label-supported 7-day blinatumomab infusion bags, age/BSA -adapted graded escalation, and dose-capped, washout-protected InO with vial sharing—enabled MRD-negative status and allo-HSCT in all patients with 0% NRM and encouraging early survival outcomes in a high-risk real-world cohort. Larger cohorts and prospective validation are warranted."

Clinical • Minimal residual disease • Real-world • Real-world evidence • Acute Lymphocytic Leukemia • Bone Marrow Transplantation • CNS Disorders • Epilepsy • Hematological Malignancies • Leukemia

LONG-TERM OUTCOMES OF ADULT PH+ ALL TREATED WITH DASATINIB OR IMATINIB BEFORE THE BLINATUMOMAB ERA: A RETROSPECTIVE ANALYSIS OF 250 PATIENTS FROM THE PALG REGISTRY (EBMT 2026) - "Background: The prognosis of Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph+ ALL) has improved substantially with the introduction of tyrosine kinase inhibitors (TKIs). In this pre-blinatumomab era subgroup analysis, adults with Ph+ ALL undergoing allo-HSCT achieved favorable long-term outcomes. Despite being part of a clinically high-risk subgroup (imatinib resistance or central nervous system involvement), patients receiving dasatinib demonstrated promising 10-year OS probability, exceeding that of imatinib and yielding statistical significance compared to that the Ph-negative ALL group. Rates, grades and involved sites of aGvHD, cGvHD, and causes of death did not differ significantly between groups, suggesting that survival differences may be driven mainly by disease control rather than transplant-related toxicity."

Retrospective data • Acute Graft versus Host Disease • Acute Lymphocytic Leukemia • Bone Marrow Transplantation • Chronic Graft versus Host Disease • Graft versus Host Disease • Hematological Malignancies • Immunology • Leukemia

THIRD-LINE TREATMENT OF CHRONIC MYELOID LEUKEMIA WITH TKI IN THE POST-BMT SETTING IN PATIENT WITH POSITIVE MRD (EBMT 2026) - "Starts on Dasatinib 100 mg per day, after one year only achieves complete hematologic response (CHR), remaining qPCR BCR-ABL: 72%IS; T315I mutation by PCR: undetected. Switch of therapy with Nilotinib 800 mg per day with no molecular response in 6 months (qPCR BCR-ABL: 44%IS)...Ponatinib was again discontinued due to hematologic toxicity.Starts oh Asciminib by day 124, achieving MR 4.0 by day 195 which is maintained by day 395... This clinical case shows that there still cases of chronic myeloid leukemia resistant to second generation TKI, even with early initiation at diagnosis. Toxicity is often associated with resistance. In our case, starting Ascminib as maintenance treatment post BMT, instead of Ponatinib due to hematologic and cardiologic toxicity, had a major impact on response achieving MR 4.0 sustained with no toxicity associated."

Clinical • Chronic Myeloid Leukemia • Hematological Malignancies • Leukemia • ABL1 • BCR

ASCIMINIB AS BRIDGE TO ALLOGENEIC-HEMOPOIETIC STEM CELL TRANSPLANT (ALLO-HSCT) IN A MULTICENTER CHRONIC MYELOID LEUKEMIA (CML) PATIENTS' COHORT (EBMT 2026) - " In our heavily pre-treated cohort, median TKIs lines before Asciminib was 4, among which 11/13 were previous Ponatinib exposed. In conclusion, in TKIs resistant CML, allo-HSCT remains the best clinical option, with excellent results in terms of deep molecular response and limited incidence of complications. In our cohort of advanced-lines patients, the use of Asciminib seems to be a potential bridge strategy for allo-HSCT, although the discrete incidence of related adverse events. Further studies in larger cohorts are warranted in order to confirm these results and drive clinical decisions."

Clinical • Acute Graft versus Host Disease • Bone Marrow Transplantation • Chronic Graft versus Host Disease • Chronic Myeloid Leukemia • CNS Disorders • Graft versus Host Disease • Hematological Malignancies • Leukemia • Transplantation • ABL1

Drug Combination to Overcome Resistance in CML (ICKSH 2026) - "Early -phase studies indicate that combining asciminib with imatinib, nilotinib, or dasatinib is feasible in patients with CP -CML...In preclinical models ponatinib and asciminib have been shown to be able to provide synergistic inhibit ion of BCR -ABL1, suppressing the emergence of resistant clones and restoring efficacy against compound mutants that are refractory to either agent alone...Anti -apoptotic agents such as venetoclax have shown synergistic pro -apoptotic effects when combined with TKIs in cell lines and primary resistant cells...Other therapeutic combinations may also be of interest, particularly those aimed at modulating the leukemic microenvironment or enhancing immune -mediated elimination of leukemic cells. In conclusion, combination therapies designed to overcome resistant CML represent promising strategies; however, their use should be carefully evaluated within the context of well -designed clinical trials and tailored to address the molecular..."

Chronic Myeloid Leukemia • Hematological Malignancies • Leukemia • ABL1